key: cord-0025379-zuf1b2zx
authors: Gue, Ying X.; Pula, Giordano; Lip, Gregory Y.H.
title: Crizanlizumab: A CRITICAL Drug During a CRITICAL Time?
date: 2021-12-27
journal: JACC Basic Transl Sci
DOI: 10.1016/j.jacbts.2021.10.013
sha: 1564d7e559a2c10047f97b6beaacbc3d01e5f5d2
doc_id: 25379
cord_uid: zuf1b2zx

[Figure: see text]

The inhibition of P-selectin has previously been shown in animal models to promote thrombus resolution or, in other words, to improve endogenous fibrinolysis, and the changes in thrombotic profiles seen in this study support this observation (5) .

Crizanlizumab has also been trialed in phase 3 studies among patients with sickle-cell disease and has been shown to reduce the incidence of vasoocclusive crises without increasing the risk for bleeding (6) 

Immunoinflammatory, thrombohaemostatic, and cardiovascular mechanisms in COVID-19

Effect of crizanlizumab, a P-selectin inhibitor

Pharmacological agents targeting thromboinflammation in COVID-19: review and implications for future research

Personalizing antithrombotic therapy in COVID-19: role of thromboelastography and thromboelastometry

Pselectin inhibition therapeutically promotes thrombus resolution and prevents vein wall fibrosis better than enoxaparin and an inhibitor to von Willebrand factor

Crizanlizumab versus placebo, with or without hydroxyurea/hydroxycarbamide, in adolescent and adult patients with sickle cell disease and vasoocclusive crises: a randomized, double-blind, phase III study (STAND)